Physician profile
Michael J Kraut
NPI 1114926805
$42,288.45
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $18K · 2021: $116 · 2022: $1,615.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36,741.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $4,268.80 | 2019-2020 | |
| Celgene Corporation | $613.89 | 2019-2022 | |
| Genentech USA, INC. | $154.28 | 2019 | |
| Lilly USA, LLC | $90.74 | 2019 | |
| Merck Sharp & Dohme LLC | $62.44 | 2019 | |
| Amgen INC. | $57.43 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $43.18 | 2019 | |
| Eisai INC. | $37.32 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.20 | 2019 | |
| Seagen INC. | $17.39 | 2019 | |
| Clovis Oncology, INC. | $17.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $15.77 | 2019 | |
| Puma Biotechnology, INC. | $13.60 | 2019 | |
| Foundation Medicine, INC. | $13.56 | 2019 | |
| Astellas Pharma US INC | $12.96 | 2019 | |
| Shire North American Group INC | $12.88 | 2019 | |
| Pfizer INC. | $11.86 | 2019 | |
| Emd Serono, INC. | $11.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kraut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.